SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Henriksson Roger) "

Sökning: WFRF:(Henriksson Roger)

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Ljuslinder, Ingrid, 1968-, et al. (författare)
  • ErbB 1-4 expression alterations in primary colorectal cancers and their corresponding metastases
  • 2009
  • Ingår i: Anticancer Research. - 0250-7005. ; 29:5, s. 1489-1494
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: EGFR (epidermal growth factor receptor) targeted therapies are important new tools in colorectal cancer treatment. EGFR analysis of the primary tumour was previously recommended to identify patients who will benefit from the EGFR targeted therapy. Previous studies have displayed diverging results regarding the expression of EGFR in the primary tumour compared to the metastases. The present study was performed to investigate whether EGFR and ErbB2-4 expression differed between 64 primary tumours and their corresponding metastases. PATIENTS AND METHODS: EGFR and ErbB2-4 expression were analysed in the primary tumour and in the corresponding metastases using immunohistochemistry (IHC). RESULTS: In 49/64 samples (76%), the primary tumours were EGFR positive; in 33% (16/49) of EGFR positive samples, the tumours lost the EGFR expression in the metastasis compared to the primary tumour. From the primary tumours, 15/64 (23%) were negative and 5 of these (33%) developed EGFR expression in the metastasis. ErbB2, ErbB3, and ErbB4 expression was evident in 54%, 67%, and 81%, respectively. There was no significant difference between ErbB2, ErbB3, and ErbB4 expression in primary tumours and metastases. The co-expression of the ErbB family members was also analysed, with a significant increase of ErbB3/ErbB4 co-expression in late stage tumours. CONCLUSION: The EGFR expression was lost in 33% of metastasising primary colorectal cancer tumours, a finding that agrees with at least one previous study. Thus, the present results clearly implicate the need for EGFR analysis of both the primary tumour and metastases to accurately determine EGFR status when considering the use of EGFR targeted therapies.
  •  
2.
  • Ljuslinder, Ingrid, 1968-, et al. (författare)
  • LRIG1 expression in colorectal cancer
  • 2007
  • Ingår i: Acta Oncologica. - 0284-186X. ; 46:8, s. 1118-1122
  • Tidskriftsartikel (refereegranskat)
  •  
3.
  • Malmström, Annika, et al. (författare)
  • Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: : the Nordic randomised, phase 3 trial
  • 2012
  • Ingår i: The Lancet Oncology. - Elsevier. - 1470-2045. ; 13:9, s. 916-926
  • Tidskriftsartikel (refereegranskat)abstract
    • Background Most patients with glioblastoma are older than 60 years, but treatment guidelines are based on trials in patients aged only up to 70 years. We did a randomised trial to assess the optimum palliative treatment in patients aged 60 years and older with glioblastoma. less thanbrgreater than less thanbrgreater thanMethods Patients with newly diagnosed glioblastoma were recruited from Austria, Denmark, France, Norway, Sweden, Switzerland, and Turkey. They were assigned by a computer-generated randomisation schedule, stratified by centre, to receive temozolomide (200 mg/m(2) on days 1-5 of every 28 days for up to six cycles), hypofractionated radiotherapy (34.0 Gy administered in 3.4 Gy fractions over 2 weeks), or standard radiotherapy (60.0 Gy administered in 2.0 Gy fractions over 6 weeks). Patients and study staff were aware of treatment assignment. The primary endpoint was overall survival. Analyses were done by intention to treat. This trial is registered, number ISRCTN81470623. less thanbrgreater than less thanbrgreater thanFindings 342 patients were enrolled, of whom 291 were randomised across three treatment groups (temozolomide n=93, hypofractionated radiotherapy n=98, standard radiotherapy n=100) and 51 of whom were randomised across only two groups (temozolomide n=26, hypofractionated radiotherapy n=25). In the three-group randomisation, in comparison with standard radiotherapy, median overall survival was significantly longer with temozolomide (8.3 months [95% CI 7.1-9.5; n=93] vs 6.0 months [95% CI 5.1-6.8; n=100], hazard ratio [HR] 0.70; 95% CI 0.52-0.93, p=0.01), but not with hypofractionated radiotherapy (7.5 months [6.5-8.6; n=98], HR 0.85 [0.64-1.12], p=0.24). For all patients who received temozolomide or hypofractionated radiotherapy (n=242) overall survival was similar (8.4 months [7.3-9.4; n=119] vs 7.4 months [6.4-8.4; n=123]; HR 0.82, 95% CI 0.63-1.06; p=0.12). For age older than 70 years, survival was better with temozolomide and with hypofractionated radiotherapy than with standard radiotherapy (HR for temozolomide vs standard radiotherapy 0.35 [0.21-0.56], pandlt;0.0001; HR for hypofractionated vs standard radiotherapy 0.59 [95% CI 0.37-0.93], p=0.02). Patients treated with temozolomide who had tumour MGMT promoter methylation had significantly longer survival than those without MGMT promoter methylation (9.7 months [95% CI 8.0-11.4] vs 6.8 months [5.9-7.7]; HR 0.56 [95% CI 0.34-0.93], p=0.02), but no difference was noted between those with methylated and unmethylated MGMT promoter treated with radiotherapy (HR 0.97 [95% CI 0.69-1.38]; p=0.81). As expected, the most common grade 3-4 adverse events in the temozolomide group were neutropenia (n=12) and thrombocytopenia (n=18). Grade 3-5 infections in all randomisation groups were reported in 18 patients. Two patients had fatal infections (one in the temozolomide group and one in the standard radiotherapy group) and one in the temozolomide group with grade 2 thrombocytopenia died from complications after surgery for a gastrointestinal bleed. less thanbrgreater than less thanbrgreater thanInterpretation Standard radiotherapy was associated with poor outcomes, especially in patients older than 70 years. Both temozolomide and hypofractionated radiotherapy should be considered as standard treatment options in elderly patients with glioblastoma. MGMT promoter methylation status might be a useful predictive marker for benefit from temozolomide.
  •  
4.
  •  
5.
  • Ostrom, Quinn T., et al. (författare)
  • Sex-specific gene and pathway modeling of inherited glioma risk
  • 2019
  • Ingår i: Neuro-Oncology. - Oxford University Press. - 1522-8517. ; 21:1, s. 71-82
  • Tidskriftsartikel (refereegranskat)abstract
    • Background To date, genome-wide association studies (GWAS) have identified 25 risk variants for glioma, explaining 30% of heritable risk. Most histologies occur with significantly higher incidence in males, and this difference is not explained by currently known risk factors. A previous GWAS identified sex-specific glioma risk variants, and this analysis aims to further elucidate risk variation by sex using gene- and pathway-based approaches. Methods Results from the Glioma International Case-Control Study were used as a testing set, and results from 3 GWAS were combined via meta-analysis and used as a validation set. Using summary statistics for nominally significant autosomal SNPs (P < 0.01 in a previous meta-analysis) and nominally significant X-chromosome SNPs (P < 0.01), 3 algorithms (Pascal, BimBam, and GATES) were used to generate gene scores, and Pascal was used to generate pathway scores. Results were considered statistically significant in the discovery set when P < 3.3 x 10(-6) and in the validation set when P < 0.001 in 2 of 3 algorithms. Results Twenty-five genes within 5 regions and 19 genes within 6 regions reached statistical significance in at least 2 of 3 algorithms in males and females, respectively. EGFR was significantly associated with all glioma and glioblastoma in males only and a female-specific association in TERT, all of which remained nominally significant after conditioning on known risk loci. There were nominal associations with the BioCarta telomeres pathway in both males and females. Conclusions These results provide additional evidence that there may be differences by sex in genetic risk for glioma. Additional analyses may further elucidate the biological processes through which this risk is conferred.
  •  
6.
  • Roodakker, Kenney R., et al. (författare)
  • PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status
  • 2016
  • Ingår i: OncoTarget. - IMPACT JOURNALS LLC. - 1949-2553. ; 7:45, s. 72431-72442
  • Tidskriftsartikel (refereegranskat)abstract
    • PROX1 is a transcription factor with an essential role in embryonic development and determination of cell fate. In addition, PROX1 has been ascribed suppressive as well as oncogenic roles in several human cancers, including brain tumors. In this study we explored the correlation between PROX1 expression and patient survival in high-grade astrocytomas. For this purpose, we analyzed protein expression in tissue microarrays of tumor samples stratified by patient age and IDH mutation status. We initially screened 86 unselected high-grade astrocytomas, followed by 174 IDH1-R132H1 immunonegative glioblastomas derived from patients aged 60 years and older enrolled in the Nordic phase III trial of elderly patients with newly diagnosed glioblastoma. Representing the younger population of glioblastomas, we studied 80 IDH-wildtype glioblastomas from patients aged 18-60 years. There was no correlation between PROX1 protein and survival for patients with primary glioblastomas included in these cohorts. In contrast, high expression of PROX1 protein predicted shorter survival in the group of patients with IDH-mutant anaplastic astrocytomas and secondary glioblastomas. The prognostic impact of PROX1 in IDH-mutant 1p19q non-codeleted high-grade astrocytomas, as well as the negative findings in primary glioblastomas, was corroborated by gene expression data extracted from the Cancer Genome Atlas. We conclude that PROX1 is a new prognostic biomarker for 1p19q non-codeleted high-grade astrocytomas that have progressed from pre-existing lowgrade tumors and harbor IDH mutations.
7.
  • Weller, Michael, et al. (författare)
  • EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma
  • 2014
  • Ingår i: The Lancet Oncology. - 1470-2045. ; 15:9, s. E395-E403
  • Forskningsöversikt (övrigt vetenskapligt)abstract
    • This guideline provides recommendations for diagnostic and therapeutic procedures for patients with malignant gliomas. We differentiate evidence-based standards from reasonable options or non-evidence-based measures that should no longer be considered. The recommendations herein should provide a framework and assurance for the choice of diagnostic procedures and therapeutic measures and aim to reduce complications from unnecessary treatment and cost. The guideline contributes to a critical appreciation of concurrent drugs with a focus on the controlled use of anticonvulsants and steroids. It should serve as a guideline for all professionals involved in the diagnostics and care of glioma patients and also as a source of knowledge for insurance companies and other institutions involved in the cost regulation of cancer care in Europe. Implementation of the recommendations summarised here will need interdisciplinary structures of care for patients with brain tumours and structured processes of diagnostic and therapeutic procedures.
  •  
8.
  •  
9.
  •  
10.
  • Andersson, Ronny, et al. (författare)
  • Effects of interferon-[alpha], verapamil and dacarbazine in the treatment of advanced malignant melanoma
  • 2003
  • Ingår i: Melanoma research. - 0960-8931. ; 13:1, s. 87-91
  • Tidskriftsartikel (refereegranskat)abstract
    • Treatment of patients with metastatic melanoma with either dacarbazine (DTIC) or interferon-[alpha] (IFN[alpha]) as single drugs, or in combination, results in a response rate of approximately 15–20%. This study evaluated the activity and toxicity following treatment with a combination of DTIC, IFN[alpha]2b and verapamil (VPL). Thirty patients with disseminated metastatic melanoma received DTIC 250 mg/m2 on days 1–5 of a 4 week schedule, IFN[alpha]2b 3 MIU on days 1–5 each week, and VPL 80 mg three times a day throughout the cycle, until either disease progression or serious toxicity was observed. Among the 28 evaluable patients, there were four complete responses (CRs), five partial responses (PRs) and eight patients with stable disease (SD). The overall response rate (CR + PR) was 32%. Two patients with a CR were long-term survivors (45 and 34 months) and a third is still in complete remission after 49 months. The fourth CR patient relapsed and died with progressive brain metastases after 8 months. Among the eight patients with SD, one survived for 22 months and another for 34 months. Despite one toxic death, these results suggest that this treatment regimen is well tolerated and seems to be more effective than DTIC alone in a subset of patients. A controlled randomized study would be required to determine the value of adding VPL and IFN[alpha]2b to DTIC.
  •  
Skapa referenser, mejla, bekava och länka
Åtkomst
fritt online (33)
Typ av publikation
tidskriftsartikel (208)
annan publikation (12)
forskningsöversikt (9)
konferensbidrag (5)
bokkapitel (3)
doktorsavhandling (2)
visa fler...
visa färre...
Typ av innehåll
refereegranskat (189)
övrigt vetenskapligt (49)
populärvet., debatt m.m. (1)
Författare/redaktör
Henriksson, Roger, (229)
Hedman, Håkan, (50)
Andersson, Ulrika, (26)
Johansen, Christoffe ... (23)
Feychting, Maria (22)
Bergenheim, A Tommy, (22)
visa fler...
Ahlbom, Anders (21)
Wick, Wolfgang (20)
Saran, Frank, (18)
Malmer, Beatrice (18)
Nishikawa, Ryo (18)
Bergqvist, Michael, (17)
Johansson, Mikael, (17)
Asklund, Thomas, (16)
Lenner, Per, (15)
Hemminki, Kari, (15)
Brännström, Thomas, (14)
Lönn, Stefan (14)
Försti, Asta, (14)
Bergström, Stefan (14)
Mason, Warren (14)
Chinot, Olivier L. (14)
Johansson, Robert, (13)
Lonn, S, (13)
Grankvist, Kjell, (13)
Melin, Beatrice S., (13)
Cloughesy, Timothy (13)
Ekman, Simon (12)
Melin, Beatrice, (12)
Nilsson, Jonas, (11)
Swerdlow, Anthony (11)
Wibom, Carl, (11)
Malmström, Annika, (11)
Holmlund, Camilla, (11)
Giles, Graham G (10)
Yeager, Meredith (10)
Auvinen, Anssi (10)
Rajaraman, Preetha (10)
Wang, Zhaoming, (10)
Garcia, Josep (10)
Carreon, Tania (10)
Chanock, Stephen J (9)
Stevens, Victoria L (9)
Hallmans, Göran, (9)
Gaziano, J Michael (9)
Guo, Dongsheng, (9)
Kvarnbrink, Samuel, (9)
Holgersson, Georg, (9)
Bergström, Per, (9)
Peters, Ulrike, (9)
visa färre...
Lärosäte
Umeå universitet (220)
Karolinska Institutet (52)
Uppsala universitet (34)
Lunds universitet (31)
Linköpings universitet (17)
Göteborgs universitet (10)
visa fler...
Kungliga Tekniska Högskolan (1)
Stockholms universitet (1)
visa färre...
Språk
Engelska (222)
Svenska (4)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (165)
Naturvetenskap (8)
Teknik (4)
Samhällsvetenskap (2)
Lantbruksvetenskap (1)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy